Literature DB >> 8117128

Guidelines for the safe administration of inhaled nitric oxide.

O I Miller1, D S Celermajer, J E Deanfield, D J Macrae.   

Abstract

Inhaled nitric oxide (NO) is a selective pulmonary vasodilator, potentially useful in the treatment of pulmonary hypertension and ventilation-perfusion mismatch. High doses of inhaled NO and its oxidative product nitrogen dioxide (NO2) may cause acute lung injury. Using a standard infant ventilator, ventilator circuit and test lung, an administration and monitoring strategy has been defined for inhaled NO and these observations validated in eight ventilated infants. In 90% oxygen, doses of inhaled NO > or = 80 parts per million may result in toxic NO2 concentrations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8117128      PMCID: PMC1060988          DOI: 10.1136/fn.70.1.f47

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  17 in total

1.  Safety guidelines for use of nitric oxide.

Authors:  L Foubert; B Fleming; R Latimer; M Jonas; A Oduro; C Borland; T Higenbottam
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; S R Neish; E Shaffer; S H Abman
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

3.  Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects.

Authors:  A Haydar; T Malhere; P Mauriat; D Journois; P Pouard; N Denis; D Lefèbvre; D Safran; P Vouhé
Journal:  Lancet       Date:  1992 Dec 19-26       Impact factor: 79.321

4.  Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

Authors:  C Frostell; M D Fratacci; J C Wain; R Jones; W M Zapol
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

Review 5.  Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein.

Authors:  L J Ignarro
Journal:  Circ Res       Date:  1989-07       Impact factor: 17.367

6.  Inhalation of nitric oxide reduced pulmonary hypertension after cardiac surgery in a 3.2-kg infant.

Authors:  H Selldén; P Winberg; L E Gustafsson; B Lundell; K Böök; C G Frostell
Journal:  Anesthesiology       Date:  1993-03       Impact factor: 7.892

7.  Intraoperative use of inhaled low-dose nitric oxide.

Authors:  O I Miller; J James; M J Elliott
Journal:  J Thorac Cardiovasc Surg       Date:  1993-03       Impact factor: 5.209

8.  Safety requirement for use of inhaled nitric oxide in neonates.

Authors:  M Bouchet; M H Renaudin; C Raveau; J C Mercier; M Dehan; V Zupan
Journal:  Lancet       Date:  1993-04-10       Impact factor: 79.321

9.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J D Roberts; D M Polaner; P Lang; W M Zapol
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

10.  Inhaled nitric oxide for the adult respiratory distress syndrome.

Authors:  R Rossaint; K J Falke; F López; K Slama; U Pison; W M Zapol
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

View more
  12 in total

1.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

2.  Occupational exposure during nitric oxide inhalational therapy in a pediatric intensive care setting.

Authors:  D G Markhorst; T Leenhoven; J W Uiterwijk; J Meulenbelt; A J van Vught
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

3.  Changes in alveolar-arterial oxygen difference and oxygenation index during low-dose nitric oxide inhalation in 15 newborns with severe respiratory insufficiency.

Authors:  Z Stranák; V Zábrodský; J Simák
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

4.  Nitric oxide degradation of heparin and heparan sulphate.

Authors:  R E Vilar; D Ghael; M Li; D D Bhagat; L M Arrigo; M K Cowman; H S Dweck; L Rosenfeld
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

Review 5.  Treatment of newborn infants with inhaled nitric oxide.

Authors:  R H Mupanemunda; A D Edwards
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-03       Impact factor: 5.747

6.  Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension.

Authors:  M I Turanlahti; P O Laitinen; S J Sarna; E Pesonen
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

Review 7.  Nitric Oxide Therapy for Diabetic Wound Healing.

Authors:  Maggie J Malone-Povolny; Sara E Maloney; Mark H Schoenfisch
Journal:  Adv Healthc Mater       Date:  2019-01-15       Impact factor: 9.933

Review 8.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

9.  Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn.

Authors:  J F Tolsa; J Cotting; N Sekarski; M Payot; J L Micheli; A Calame
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-05       Impact factor: 5.747

10.  Propagation of nitric oxide pools during controlled mechanical ventilation.

Authors:  J W Skimming; P J Stephan; P B Blanch; M J Banner
Journal:  J Clin Monit Comput       Date:  1998-04       Impact factor: 2.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.